News | November 02, 2023
Zydus acquires UK based LiqMeds Group
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
The companies plan to start a pivotal Phase 3 trial in the coming months
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
The plant has a capacity for extraction of 2500 mt of poppy straw and 300 mt poppy gum per year
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
Subscribe To Our Newsletter & Stay Updated
